CervoMed Inc. announced that its drug candidate neflamapimod has been granted an Innovation Passport to enter the UK’s Innovative Licensing and Access Pathway (ILAP) for the treatment of dementia with Lewy bodies (DLB). This designation, awarded on August 4, 2026, provides early coordination with UK regulators and health technology assessment bodies to potentially accelerate market access. The company is currently seeking a strategic partner to advance neflamapimod into a Phase 3 trial for DLB. CervoMed Inc. operates in the biotechnology industry, developing treatments for age-related brain disorders.

CervoMed Inc. announced clinical, plasma biomarker, and imaging data for its lead drug candidate, neflamapimod, in treating dementia with Lewy bodies, which was presented at the Alzheimer's Association International Conference 2026. CervoMed Inc. is a biotechnology company focused on developing therapeutic solutions for neurodegenerative diseases.

CervoMed Inc. announced on July 9, 2026, that it has completed enrollment in its Phase 2a clinical study of neflamapimod for treating nonfluent variant primary progressive aphasia, a form of frontotemporal dementia. CervoMed Inc. is a biotechnology company focused on developing therapeutic solutions for neurodegenerative diseases.

CervoMed Inc. closed a registered direct offering of 2,500,000 shares of common stock at $4.00 per share. CervoMed Inc. is a biotechnology company focused on developing medical devices and therapies for treating inflammatory and inflammatory-related diseases.

On June 18, 2026, CervoMed Inc. entered into a Securities Purchase Agreement for a registered direct offering of 2,500,000 shares of common stock at $4.00 per share, generating aggregate gross proceeds of $10.0 million. The offering is expected to close on or about June 22, 2026, with net proceeds intended for working capital and general corporate purposes. H.C. Wainwright & Co., LLC served as the exclusive placement agent, receiving a 6.0% cash fee, a 1.0% management fee, and warrants to purchase common stock equal to 6.0% of the shares issued at an exercise price of $5.00 per share. The company agreed to a 30-day lock-up period on further equity issuances and a six-month restriction on variable rate transactions. CervoMed Inc. is a biotechnology company that develops medical devices and therapies.